Skip to main content
. 2020 Feb 18;11(2):129. doi: 10.1038/s41419-020-2314-6

Fig. 7. SR9009 alleviates disease severity and local bone resorption in CIA mice.

Fig. 7

a DBA/1 mice were immunized on days 0 and 21 and administered SR9009 every 2 days after the booster immunization. Representative hind paws on day 48. Mean arthritic score (left) and hind-paw thickness (right) were evaluated in mice with CIA administered PBS and SR9009 (50 or 100 mg/kg). Compared with the sham group, *p < 0.05; compared with the vehicle group, #p < 0.05 or &p < 0.01. b Representative micro-CT images of the hind paws of CIA mice on day 48. Data are means ± SEM, n = 8–10 mice per group. c Serum levels of proinflammatory cytokines, RANKL, and OPG in mice with CIA as determined by ELISA. Serum samples were collected on day 48 from mice with CIA and those administered SR9009. Data are means ± SEM (n = 8–10 mice per group). *p < 0.05, **p < 0.01 versus the vehicle group. d Representative images of hematoxylin-eosin staining of ankle and knee joint sections are shown (original magnification 4×, scale bar = 1000 μm or original magnification 10×, scale bar = 100 μm).